Ashish Kamat introduces Stephen B. Williams who discusses findings from his study on blue light cystoscopy in bladder cancer treatment, conducted within the VA healthcare system. The study utilized a propensity score-matched analysis to compare the outcomes of blue light versus white light cystoscopy, focusing on bladder cancer recurrence, progression, and overall survival. The analysis revealed significant improvements in all measured outcomes for patients treated with blue light cystoscopy. This large-scale study supports the effectiveness of blue light cystoscopy in managing bladder cancer, particularly in reducing recurrence and improving survival, even within a veteran population with equal access to healthcare services. Dr. Williams emphasizes the study's relevance in guiding precise treatment approaches in urology.

Biographies:

Stephen B. Williams, MD, MS, FACS, Chief, Division of Urology, Director of Urologic Oncology, Director of Urologic Research, Co-Director of Department of Surgery Clinical Outcomes Research Program, Medical Director of High-Value Care, University of Texas Medical Branch (UTMB) Health System, Galveston, TX

Ashish Kamat, MD, MBBS, Professor of Urology and Wayne B. Duddleston Professor of Cancer Research, University of Texas, MD Anderson Cancer Center, Houston, TX